5-Amino-1MQvsHumanin

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytoplasmic enzyme that is significantly overexpressed in white adipose tissue of obese individuals. NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) using S-adenosyl methionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosyl homocysteine. This reaction effectively depletes two critical metabolic cofactors — NAD+ precursors and SAM — from fat cells.

By inhibiting NNMT, 5-Amino-1MQ preserves the cellular pools of both nicotinamide (which feeds NAD+ biosynthesis via the salvage pathway) and SAM (the universal methyl donor required for hundreds of methylation reactions). Increased NAD+ availability activates sirtuin enzymes (particularly SIRT1 and SIRT3), which are master regulators of cellular metabolism — they deacetylate and activate PGC-1alpha (promoting mitochondrial biogenesis), enhance fatty acid oxidation, and suppress lipogenic gene expression. The net effect is that adipocytes shift from a fat-storing to a fat-burning metabolic state.

In preclinical models, NNMT inhibition reduced adipocyte size, decreased total body fat mass, and increased energy expenditure without affecting food intake — suggesting the weight loss mechanism is primarily metabolic rather than appetite-driven. Additionally, NNMT inhibition has shown improvements in insulin sensitivity and reductions in plasma cholesterol. However, all published efficacy data comes from cell culture and rodent studies; no human clinical trials have been completed, so the translational relevance remains uncertain.

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.